Serum amyloid A1 and plasminogen as predictory proteins to monitor the progression of preleukemic diseases towards acute lymphoblastic leukaemia

Raza, Syed Kashif; Shamsi, Tahir; Musharraf, Syed Ghulam

doi:10.1039/c7ra03445h

Cited by 2 publications

(2 citation statements)

References 42 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, twelve studies in our meta-analysis both reported elevated levels of SAA are significantly associated with outcome in patients solid tumors. Latest article suggested that SAA maybe considered as a potential molecule to monitor the progression of acute lymphoblastic leukaemia [ 33 ]. However, until now, there are rare studies reported the relation between SAA and prognosis of patients with hematological malignancies.…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of serum amyloid A in solid tumors: a meta-analysis

et al. 2019

View full text Add to dashboard Cite

BackgroundPrevious studies have demonstrated that serum amyloid A (SAA) levels are correlated with the clinical outcomes of solid tumors. However, the available data have not been systematically evaluated. The objective of the present meta-analysis was to explore the prognostic value of SAA levels in solid tumors.MethodsEligible studies were identified from the PubMed, EMBASE and Science Citation Index electronic databases. The clinical characteristics, disease/progression-free survival (DFS/PFS) and overall survival (OS) were extracted from the eligible studies. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated with Stata 12.0 software. We also performed subgroup, meta-regression and sensitivity analyses.ResultsIn total, 12 eligible studies including 2749 patients were enrolled in the present meta-analysis. The pooled HRs with 95% CIs showed that elevated levels of SAA were significantly associated with poor OS (HR = 3.01, 95% CI 1.96–4.63) and DFS/PFS (HR = 1.67, 95% CI 1.31–2.12) in patients with solid tumors. Although publication bias was seem found in the studies with regard to OS, a further trim and fill analysis revealed that the adjusted HR was 3.02 (95% CI 1.96–4.63), which was close to the original HR. Subgroup analysis confirmed an elevated level of SAA as a strong prognostic marker in patients with solid tumors, regardless of tumor type, detection method, cut-off value, sample size, area and variance analyses.ConclusionOur meta-analysis indicated that elevated levels of SAA might be an unfavorable prognostic marker for OS in patients with solid tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

The prognostic value of serum amyloid A in solid tumors: a meta-analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Over the past forty years, mounting evidence has shown the almost omnipresent nature of Serum Amyloid A (SAA) in the blood of cancer patients [7,8,[17][18][19][20][21][22][23][9][10][11][12][13][14][15][16]] and a plethora of cell types -not only hepatocytes as originally believed [24]. The most notable discovery was that SAA is upregulated in many cell types, including macrophages, adipocytes, and broblasts which are commonly associated with tumors [6], in addition to cancer cells themselves [12,19,22,23,[25][26][27][28][29][30].…”

mentioning

confidence: 99%

Beyond the acute-phase response: systemic Serum Amyloid A 1/2 promotes inflammasome activation, apoptosis, and necrosis in breast cancer

Olivier

Fourie

Plessis

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Past research has identified the family of Serum Amyloid A (SAA) proteins to be intricately involved in inflammatory signaling and various disease pathologies. In cancer patients, SAA proteins have been reported to be upregulated in blood and tumor tissue, correlating in many instances with disease progression. However, the exact role of SAA proteins in cancer pathology remains to be fully elucidated. We, therefore, investigated systemic SAA1 and SAA2 (SAA1/2) in modulating the inflammasome, cell cycle, apoptosis, and epithelial-to-mesenchymal transition (EMT). Methods Breast cancer allografts were established in wild-type mice (WT), and mice lacking the SAA1/2 orthologs (SAADKO). Subsequently, tumor volume was monitored, species survival determined, the inflammatory profiles of mice assessed with a multiplex assay, and tumor molecular biology and histology characterized with western blotting and H&E histological staining. Results WT tumor-bearing mice had increased levels of plasma SAA compared to WT control mice, while SAADKO control and tumor-bearing mice presented with lower levels of SAA in their plasma. SAADKO tumor-bearing mice also displayed significantly lower concentrations of the systemic inflammatory markers, IL-1β, IL-6, and IL-10 compared to WT tumor-bearing mice. Tumors from SAADKO mice overall had lower levels of SAA compared to tumors from WT mice, decreased apoptotic (cytochrome c, caspases 9/3, PARP), and inflammasome (NFκB, caspase 1, NLRP3) signaling, with little to no tumor necrosis. Conclusions We show that systemic SAA1/2 promotes the activation of the NLRP3 inflammasome in breast cancer tumors and the generation of pro-inflammatory cytokines, which promotes apoptosis and tumor necrosis. Based on these findings, we hypothesize that SAA1/2-mediated necrosis is due to NLRP3-mediated pore formation in membranes, while apoptosis signaling is likely mediated via the TIF-IA-NF-κB-apoptosis axis.

show abstract

Serum amyloid A1 and plasminogen as predictory proteins to monitor the progression of preleukemic diseases towards acute lymphoblastic leukaemia

Abstract: SAA1 and plasminogen as additional predictory molecules to monitor the progression of preleukemic diseases towards ALL.

Cited by 2 publications

References 42 publications

The prognostic value of serum amyloid A in solid tumors: a meta-analysis

The prognostic value of serum amyloid A in solid tumors: a meta-analysis

Beyond the acute-phase response: systemic Serum Amyloid A 1/2 promotes inflammasome activation, apoptosis, and necrosis in breast cancer

Contact Info

Product

Resources

About